BMS-986482

BMS-986482 is an investigational small molecule anticancer drug developed by Bristol-Myers Squibb. It is being studied primarily for the treatment of advanced solid tumors, including but not limited to non-small cell lung cancer, breast cancer (including triple-negative and HER2-negative subtypes), melanoma, colorectal cancer, gastric cancer, head and neck cancers, urogenital cancers, and others. The drug acts as a TYK2 (Tyrosine kinase 2) inhibitor—a member of the Janus kinase family involved in cytokine signaling pathways that regulate immune responses and tumor progression. By inhibiting TYK2 activity, BMS-986482 aims to modulate immune signaling relevant to tumor growth and survival. Clinical trials are ongoing to evaluate its safety and efficacy both as monotherapy and in combination with other agents such as nivolumab or bevacizumab in patients with advanced or metastatic disease who have exhausted standard therapies[1][4][5][6][7].

Other names

BMS 986482BMS986482BMS-986482